BLPH VS SXTC Stock Comparison

Performance

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

SXTC
10/100

SXTC returned -87.22% in the last 12 months. Based on SPY's performance of -11.50%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

SXTC

"Analyst Price Targets" not found for SXTC

Technicals

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

SXTC
21/100

SXTC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

SXTC

"Earnings" not found for SXTC

Profit

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

SXTC
63/100

Out of the last 8 quarters, SXTC has had 7 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

SXTC
40/100

SXTC has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

China SXT Pharmaceuticals, Inc. Ordinary Shares Summary

Nasdaq / SXTC

Healthcare

Drug Manufacturers - Specialty & Generic

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

Power up your portfolio